StageZero Life Sciences (TSXV:SZLS.H) Beta: -0.0677 (As of Jun. 25, 2026)


TSXV:SZLS.H StageZero Life Sciences Ltd TSXV:SZLS.H
10 GF Score
Price C$0.04
View Full Analysis

What is StageZero Life Sciences Beta?

StageZero Life Sciences TSXV:SZLS.H 10 Beta is -0.0677 as of Jun. 25, 2026. GuruFocus rates TSXV:SZLS.H with a GF Score™ of 10/100.

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-06-25), StageZero Life Sciences's Beta is -0.0677.

StageZero Life Sciences  (TSXV:SZLS.H) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)

StageZero Life Sciences Beta Related Terms

StageZero Life Sciences Beta Historical Data

* Premium members only.

The historical data trend for StageZero Life Sciences's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

StageZero Life Sciences Beta Chart

StageZero Life Sciences Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Beta
Get a 7-Day Free Trial Premium Member Only Premium Member Only 20.55 3.92 1.15 0.76 0.30

StageZero Life Sciences Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Mar24 Jun24 Sep24
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.48 0.56 -0.04 0.27 0.31

TSXV:SZLS.H vs IDTA, TTOO, NSTM: Beta Comparison

For the Diagnostics & Research subindustry, StageZero Life Sciences's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

StageZero Life Sciences Beta vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, StageZero Life Sciences's Beta distribution charts can be found below:

* The bar in red indicates where StageZero Life Sciences's Beta falls into.


TSXV:SZLS.H
10GF Score
StageZero Life Sciences Ltd TSXV:SZLS.H
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

StageZero Life Sciences Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Frequently Asked Questions Learn more about Beta →
What does a Beta of -0.0677 mean?
StageZero Life Sciences (TSXV:SZLS.H) has a Beta of -0.0677 as of Jun. 25, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for StageZero Life Sciences and its competitors.
Is StageZero Life Sciences' Beta too high?
StageZero Life Sciences' current Beta is -0.0677. Overall, StageZero Life Sciences has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does StageZero Life Sciences' Beta compare to IDTA and TTOO?
StageZero Life Sciences' Beta of -0.0677 can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Medical Diagnostics & Research company?
A good Beta depends on the Medical Diagnostics & Research industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for StageZero Life Sciences and its competitors. StageZero Life Sciences's current Beta is -0.0677. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is StageZero Life Sciences stock overvalued right now?
StageZero Life Sciences (TSXV:SZLS.H) has a current Beta of -0.0677. The current Beta is -0.0677. StageZero Life Sciences' overall GF Score™ is 10/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For StageZero Life Sciences (TSXV:SZLS.H), the current Beta is -0.0677 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

StageZero Life Sciences Business Description

Address 70 East Beaver Creek Road, Unit 30, Richmond Hill, ON, CAN, L4B 3B2
StageZero Life Sciences Ltd is a vertically integrated healthcare company at the nexus of three sectors of healthcare; Early Cancer Detection, Liquid Biopsy, and Global Telehealth. It is focused on minimizing the risk of cancer and other chronic diseases through early detection and intervention. It continues to develop and commercialize proprietary molecular diagnostic tests for the early detection of diseases and personalized health management, with a focus on cancer-related indications. It has developed a proprietary platform technology, the Sentinel Principle, to identify novel biomarkers from whole blood. The Company's lead product, Aristotle, is a blood-based molecular diagnostic assessment that can detect an individual's current risk for potentially having a variety of cancers.
10GF Score

Get the complete analysis for TSXV:SZLS.H

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

C$0.04
Price